Working... Menu
Trial record 14 of 1893 for:    Diseases | ( Map: Puerto Rico )

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02330549
Recruitment Status : Completed
First Posted : January 5, 2015
Last Update Posted : September 27, 2017
Information provided by (Responsible Party):
Tobira Therapeutics, Inc.

Brief Summary:
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of CVC to be conducted in approximately 50 adult obese subjects (BMI ≥ 30 kg/m2) with prediabetes or type 2 diabetes mellitus and suspected NALFD.

Condition or disease Intervention/treatment Phase
Prediabetic State Non-alcoholic Fatty Liver Disease Type 2 Diabetes Mellitus Drug: Cenicriviroc 150 mg Drug: Matching placebo Phase 2

Detailed Description:

Approximately 50 adult obese subjects (BMI ≥ 30 kg/m2) with prediabetes or type 2 diabetes mellitus and suspected NALFD will be randomized into the study.

Eligible subjects will receive either CVC (n=25) or matching placebo (n=25), once daily (QD) for 24 weeks, followed by a safety follow-up visit 4 weeks after last intake of study medication.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Actual Study Start Date : June 29, 2015
Actual Primary Completion Date : August 26, 2016
Actual Study Completion Date : September 8, 2016

Arm Intervention/treatment
Experimental: Cenicriviroc 150mg
CVC 150 mg, administered orally once daily and taken every morning with food for 24 weeks
Drug: Cenicriviroc 150 mg
CVC 150 mg, administered orally once daily and taken every morning with food
Other Name: CVC 150 mg

Placebo Comparator: Matching placebo
Matching placebo, administered orally once daily and taken every morning with food for 24 weeks
Drug: Matching placebo
Matching placebo administered orally once daily and taken every morning with food

Primary Outcome Measures :
  1. Changes in Insulin Sensitivity Measured by Peripheral and Adipose Tissue [ Time Frame: 24 weeks ]
    Changes in insulin sensitivity measured by peripheral and adipose tissue over 24 weeks

Secondary Outcome Measures :
  1. Degree of Macrophage Infiltration in Subcutaneous Adipose Tissue [ Time Frame: 24 weeks ]
    Evaluate degree of macrophage infiltration in subcutaneous adipose tissue over 24 weeks of treatment

  2. Expression of Chemokine Receptors Types 2 (CCR2) and 5 (CCR5) in Subcutaneous Adipose Tissue [ Time Frame: 24 weeks ]
    Evaluate expression of chemokine receptors types 2 (CCR2) and 5 (CCR5) in subcutaneous adipose tissue

  3. Changes from Baseline in Peripheral Monocyte Subsets (CD14/CD16) [ Time Frame: 24 weeks ]
    Evaluate changes from baseline in peripheral monocyte subsets (CD14/CD16)

  4. Changes in Non-invasive Imaging by Multiparametric Magnetic Resonance Imaging (MRI) for Liver Disease (LiverMultiScan™) [ Time Frame: 24 weeks ]
    Evaluate changes in non-invasive imaging by multiparametric magnetic resonance imaging (MRI) for liver disease (LiverMultiScan™)

  5. Correlation of Non-invasive Liver Imaging Findings with Histology Results [ Time Frame: 24 weeks ]
    Evaluate correlation of non-invasive liver imaging findings with histology results

  6. Changes from Baseline in Liver Transaminases [ Time Frame: 24 weeks ]
    Evaluate changes from baseline in liver transaminases

  7. Changes from Baseline in Serum Biomarker Panel [ Time Frame: 24 weeks ]
    Evaluate changes from baseline in serum biomarker panel

  8. Changes from Baseline in Metabolic Parameters [ Time Frame: 24 weeks ]
    Evaluate changes from baseline in metabolic parameters

  9. Number and Percentage of Subjects with Adverse Events over 24 Weeks [ Time Frame: 24 weeks ]
    Evaluation of adverse events over 24 weeks of treatment

  10. Changes from Baseline in Physical Examination over 24 Weeks [ Time Frame: 24 weeks ]
    Evaluation of physical examination

  11. Changes from Baseline in Vital Signs over 24 Weeks [ Time Frame: 24 weeks ]
    Evaluation of vital signs

  12. Changes from Baseline in 12 Lead ECG over 24 weeks [ Time Frame: 24 weeks ]
    Evaluation of 12 lead ECG

  13. Pharmacokinetics (PK) of CVC in a population PK analysis [ Time Frame: 24 weeks ]
    Evaluate PK of CVC

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult male and female subjects aged between 18-75 years
  • Obesity as defined by BMI ≥ 30 kg/m2
  • Evidence of prediabetes or type 2 diabetes mellitus based on Screening laboratory values with at least one of the following criteria:
  • Fasting plasma glucose (FPG) of 100 - 270 mg/dL (5.6 - 15.0 mmol/L)
  • Hemoglobin A1c (HbA1c) of 5.7 - 10.0%
  • Subjects receiving metformin alone or in combination with a sulfonylurea (glimepiride, glipizide, glyburide, or gliclazide) must be on stable therapy for at least 90 days prior to Screening.
  • Suspected diagnosis of NAFLD warranting confirmation by liver biopsy
  • AST and ALT ≤ 5 ULN
  • Ability to understand and sign a written informed consent form
  • Females of child-bearing potential and males participating in the study must agree to use at least 2 approved barrier methods of contraception throughout the duration of the study and for 3 months after stopping study drug. Females who are postmenopausal must have documentation of cessation of menses for ≥ 12 months and serum follicle stimulating hormone (FSH) ≥ 30 mU/mL
  • Subjects receiving allowed concomitant medications need to be on stable therapy for 28 days prior to Baseline

Exclusion Criteria:

  • Use of OHAs other than metformin or sulfonylureas, including but not limited to thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, meglitinides, α-glucosidase inhibitors, colesevelam, bromocriptine, pramlintide or basal insulin within 90 days prior to Screening or anticipated use during the trial
  • Type 1 diabetes
  • HBsAg positive
  • HIV-1 or HIV-2 infection
  • HCVAb positive
  • Prior or planned liver transplantation
  • Other known causes of chronic liver disease, including alcoholic liver disease
  • History of cirrhosis and/or hepatic decompensation including ascites, encephalopathy or variceal bleeding
  • Alcohol consumption greater than 14 units/week
  • Weight reduction through bariatric surgery or planned bariatric surgery during the conduct of the study (including gastric banding)
  • Any Grade ≥ 3 laboratory abnormality as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Toxicity Grading Scale, except subjects with Grade ≥ 3 dyslipidemia with triglyceride or cholesterol elevations unless clinical assessment foresees an immediate health risk to the subject
  • Serum albumin < 3.5 g/dL
  • Serum creatinine levels ≥ 1.5 mg/dL for males or ≥ 1.4 mg/dL for females if subject is receiving metformin
  • Estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) equation
  • Platelet count < 100,000/mm3
  • Hemoglobin < 12 g/dL for males or < 11 g/dL for females
  • Females who are pregnant or breastfeeding
  • Receiving ongoing therapy with any disallowed medication at Screening
  • Allergy to the study drug or its components
  • Any other clinically significant disorders or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing and protocol requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02330549

Layout table for location information
United States, Texas
Brooke Army Medical Center
Fort Sam Houston, Texas, United States, 78234
Gastroenterology Consultants of San Antonio
Live Oak, Texas, United States, 78233
Puerto Rico
Fundación de Investigación
San Juan, Puerto Rico, 00927
Sponsors and Collaborators
Tobira Therapeutics, Inc.
Layout table for investigator information
Study Director: Eric Lefebvre, MD Allergan

Layout table for additonal information
Responsible Party: Tobira Therapeutics, Inc. Identifier: NCT02330549     History of Changes
Other Study ID Numbers: 652-2-204
First Posted: January 5, 2015    Key Record Dates
Last Update Posted: September 27, 2017
Last Verified: September 2017

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Non-alcoholic Fatty Liver Disease
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Digestive System Diseases
Diabetes Mellitus
Diabetes Mellitus, Type 2
Fatty Liver
Insulin Resistance
Prediabetic State
Hypoglycemic Agents
Physiological Effects of Drugs
CCR5 Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents